Alteration of gut microbiota in inflammatory bowel disease (IBD): Cause or consequence? IBD treatment targeting the gut microbiome

Pathogens

Volumn 8, Issue 3, 2019, Pages

  Khan, Israr ^a   Ullah, Naeem ^a   Zha, Lajia ^a   Bai, Yanrui ^a   Khan, Ashiq ^a   Zhao, Tang ^a   Che, Tuanjie ^b   Zhang, Chunjiang ^a,b  

^a LANZHOU UNIVERSITY   (China)

^b Gansu Key Laboratory of Functional Genomics and Molecular Diagnosis   (China)

Author keywords

Fecal microbiota transplantation (FMT); Gut microbiota; Inflammatory bowel disease; Pathogenesis; Prebiotics; Probiotics; Synbiotics

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; PREBIOTIC AGENT; PROBIOTIC AGENT; TOLL LIKE RECEPTOR; TRANSCRIPTOME;

BACTEROIDES FRAGILIS; BIFIDOBACTERIUM; BIFIDOBACTERIUM LONGUM; CHRONIC FATIGUE SYNDROME; CLOSTRIDIOIDES DIFFICILE; COLITIS; DISEASE ACTIVITY; DISEASE SEVERITY; DYSPEPSIA; ENTERITIS; ESCHERICHIA COLI; EUBACTERIUM; FAECALIBACTERIUM; FECAL MICROBIOTA TRANSPLANTATION; FECES MICROFLORA; GENETIC SUSCEPTIBILITY; HELICOBACTER HEPATICUS; HUMAN; IMMUNE RESPONSE; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; INTESTINE FLORA; LACHNOSPIRACEAE; LACTOBACILLUS CASEI; META ANALYSIS; MICROBIAL DIVERSITY; NONHUMAN; PHAGOCYTOSIS; PREVALENCE; PROSPECTIVE STUDY; PROTEOBACTERIA; PROTEUS MIRABILIS; REVIEW; RUMINOCOCCACEAE; SIGNAL TRANSDUCTION; STREPTOCOCCUS SALIVARIUS; SYSTEMATIC REVIEW; TH2 CELL; ULCERATIVE COLITIS; UPREGULATION;

EID: 85071736806     PISSN: None     EISSN: 20760817     Source Type: Journal    
DOI: 10.3390/pathogens8030126     Document Type: Review

References (265)

1. Mulder, D.J.; Noble, A.J.; Justinich, C.J.; Duffin, J.M. A tale of two diseases: The history of inflammatory bowel disease. J. Crohn’s Colitis 2014, 8, 341-348
2. Wijmenga, C. Expressing the differences between Crohn’s disease and ulcerative colitis. PLoS Med. 2005, 2, e230
3. Kaplan, G.G. The global burden of IBD: From 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol. 2015, 12, 720
4. Chow, D.K.; Leong, R.W.; Tsoi, K.K.; Ng, S.S.; Leung, W.K.; Wu, J.C.; Wong, V.W.; Chan, F.K.; Sung, J.J. Long-term follow-up of ulcerative colitis in the Chinese population. Am. J. Gastroenterol. 2009, 104, 647-654
5. Wang, Y.F.; Ouyang, Q.; Hu, R.W. Progression of inflammatory bowel disease in China. J. Dig. Dis. 2010, 11, 76-82
6. Ng, S.C.; Shi, H.Y.; Hamidi, N.; Underwood, F.E.; Tang, W.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Wu, J.C.; Chan, F.K. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet 2017, 390, 2769-2778
7. Thia, K.T.; Loftus, E.V., Jr.; Sandborn, W.J.; Yang, S.K. An update on the epidemiology of inflammatory bowel disease in Asia. Am. J. Gastroenterol. 2008, 103, 3167
8. Victoria, C.R.; Sassak, L.Y.; Nunes, H.R.D.C. Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of São Paulo State, Brazil. Arq. Gastroenterol. 2009, 46, 20-25
9. Ouyang, Q.; Tandon, R.; Goh, K.L.; Pan, G.Z.; Fock, K.M.; Fiocchi, C.; Lam, S.K.; Xiao, S.D. Management consensus of inflammatory bowel disease for the Asia-Pacific. J. Gastroenterol. Hepatol. 2006, 21, 1772-1782
10. Foster, A.; Jacobson, K. Changing incidence of inflammatory bowel disease: Environmental influences and lessons learnt from the South Asian population. Front. Pediatr. 2013, 1, 34
11. Sekirov, I.; Russell, S.L.; Antunes, L.C.M.; Finlay, B.B. Gut microbiota in health and disease. Physiol. Rev. 2010, 90, 859-904
12. De Souza, H.S.; Fiocchi, C. Immunopathogenesis of IBD: Current state of the art. Nat. Rev. Gastroenterol. Hepatol. 2016, 13, 13-27
13. Rosen, C.E.; Palm, N.W. Navigating the Microbiota Seas: Triangulation Finds a Way Forward. Cell Host Microbe 2018, 23, 1-3
14. Gkouskou, K.; Deligianni, C.; Tsatsanis, C.; Eliopoulos, A.G. The gut microbiota in mouse models of inflammatory bowel disease. Front. Cell. Infect. Microbiol. 2014, 4, 28
15. ® mesalamine. Clin. Pharmacol. Adv. Appl. 2012, 4, 41-50
16. MacDermott, R.P.; Green, J.A. Refractory ulcerative colitis treatment. Gastroenterol. Hepatol. 2007, 3, 64-69
17. Rhen, T.; Cidlowski, J.A. Antiinflammatory action of glucocorticoids—New mechanisms for old drugs. N. Engl. J. Med. 2005, 353, 1711-1723
18. Habens, F.; Srinivasan, N.; Oakley, F.; Mann, D.A.; Ganesan, A.; Packham, G. Novel sulfasalazine analogues with enhanced NF-kB inhibitory and apoptosis promoting activity. Apoptosis 2005, 10, 481-491
19. Nugent, S.G.; Kumar, D.; Rampton, D.S.; Evans, D.F. Intestinal luminal pH in inflammatory bowel disease: Possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 2001, 48, 571-577
20. Van Dieren, J.M.; Kuipers, E.J.; Samsom, J.N.; Nieuwenhuis, E.E.; van der Woude, C.J. Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: Their mechanisms of action and role in the treatment of IBD. Inflamm. Bowel Dis. 2006, 12, 311-327
21. Willot, S.; Noble, A.; Deslandres, C. Methotrexate in the treatment of inflammatory bowel disease: An 8-year retrospective study in a Canadian pediatric IBD center. Inflamm. Bowel Dis. 2011, 17, 2521-2526
22. Ratner, M. IL-17-targeting biologics aim to become standard of care in psoriasis. Nat. Biotechnol. 2015, 33, 3-4
23. Ogata, H.; Matsui, T.; Nakamura, M.; Iida, M.; Takazoe, M.; Suzuki, Y.; Hibi, T. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006, 55, 1255-1262
24. Triantafillidis, J.K.; Merikas, E.; Georgopoulos, F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des. Dev. Ther. 2011, 5, 185-210
25. Qin, J.; Li, R.; Raes, J.; Arumugam, M.; Burgdorf, K.S.; Manichanh, C.; Nielsen, T.; Pons, N.; Levenez, F.; Yamada, T. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464, 59-65
26. Tlaskalová-Hogenová, H.; Štěpánková, R.; Kozáková, H.; Hudcovic, T.; Vannucci, L.; Tučková, L.; Rossmann, P.; Hrnčíř, T.; Kverka, M.; Zákostelská, Z. et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: Contribution of germ-free and gnotobiotic animal models of human diseases. Cell. Mol. Immunol. 2011, 8, 110-120
27. Hoffmann, C.; Dollive, S.; Grunberg, S.; Chen, J.; Li, H.; Wu, G.D.; Lewis, J.D.; Bushman, F.D. Archaea and fungi of the human gut microbiome: Correlations with diet and bacterial residents. PLoS ONE 2013, 8, e66019
28. Frank, D.N.; Amand, A.L.S.; Feldman, R.A.; Boedeker, E.C.; Harpaz, N.; Pace, N.R. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl. Acad. Sci. USA 2007, 104, 13780-13785
29. Clemente, J.C.; Ursell, L.K.; Parfrey, L.W.; Knight, R. The impact of the gut microbiota on human health: An integrative view. Cell 2012, 148, 1258-1270
30. Turnbaugh, P.J.; Ridaura, V.K.; Faith, J.J.; Rey, F.E.; Knight, R.; Gordon, J.I. The effect of diet on the human gut microbiome: A metagenomic analysis in humanized gnotobiotic mice. Sci. Trans. Med. 2009, 1, 6-14
31. Koboziev, I.; Reinoso Webb, C.; Furr, K.L.; Grisham, M.B. Role of the enteric microbiota in intestinal homeostasis and inflammation. Free Radic. Biol. Med. 2014, 68, 122-133
32. Flint, H.J.; Scott, K.P.; Louis, P.; Duncan, S.H. The role of the gut microbiota in nutrition and health. Nat. Rev. Gastroenterol. Hepatol. 2012, 9, 577-589
33. Shreiner, A.B.; Kao, J.Y.; Young, V.B. The gut microbiome in health and in disease. Curr. Opin. Gastroenterol. 2015, 31, 69-75
34. Wu, W.; Chen, F.; Liu, Z.; Cong, Y. Microbiota-specific Th17 cells: Yin and Yang in regulation of inflammatory bowel disease. Inflamm. Bowel Dis. 2016, 22, 1473-1482
35. Bäumler, A.J.; Sperandio, V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature 2016, 535, 85-93
36. Torow, N.; Hornef, M.W. The neonatal window of opportunity: Setting the stage for life-long host-microbial interaction and immune homeostasis. J. Immunol. 2017, 198, 557-563
37. Arpaia, N.; Campbell, C.; Fan, X.; Dikiy, S.; van der Veeken, J.; Liu, H.; Cross, J.R.; Pfeffer K.; Coffer, P.J.; Rudensky, A.Y. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013, 504, 451-455
38. Hooper, L.V.; Macpherson, A.J. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat. Rev. Immunol. 2010, 10, 159-169
39. Gaboriau-Routhiau, V.; Rakotobe, S.; Lécuyer, E.; Mulder, I.; Lan, A.; Bridonneau, C.; Rochet, V.; Pisi, A.; De Paepe, M.; Brandi, G. et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 2009, 31, 677-689
40. Ivanov, I.I.; Atarashi, K.; Manel, N.; Brodie, E.L.; Shima, T.; Karaoz, U.; Wei, D.; Goldfarb, K.C.; Santee, C.A.; Lynch, S.V. et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009, 139, 485-498
41. Lee, Y.K.; Mazmanian, S.K. Microbial learning lessons: SFB educate the immune system. Immunity 2014, 40, 457-459
42. Geuking, M.B.; Cahenzli, J.; Lawson, M.A.; Ng, D.C.; Slack, E.; Hapfelmeier, S.; McCoy, K.D.; Macpherson, A.J. Intestinal bacterial colonization induces mutualistic regulatory T cell responses. Immunity 2011, 34, 794-806
43. Mazmanian, S.K.; Liu, C.H.; Tzianabos, A.O.; Kasper, D.L. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005, 122, 107-118
44. Atarashi, K.; Tanoue, T.; Oshima, K.; Suda, W.; Nagano, Y.; Nishikawa, H.; Fukuda, S.; Saito, T.; Narushima, S.; Hase, K. et al. T reg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 2013, 500, 232
45. Mucida, D.; Park, Y.; Kim, G.; Turovskaya, O.; Scott, I.; Kronenberg, M.; Cheroutre, H. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007, 317, 256-260
46. Round, J.L.; Mazmanian, S.K. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc. Natl. Acad. Sci. USA 2010, 107, 12204-12209
47. Qiu, X.; Zhang, M.; Yang, X.; Hong, N.; Yu, C. Faecalibacterium prausnitziiupregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis. J. Crohn’s Colitis 2013, 7, e558-e568
48. Ni, J.; Wu, G.D.; Albenberg, L.; Tomov, V.T. Gut microbiota and IBD: Causation or correlation? Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 573-584
49. Buttó, L.F.; Haller, D. Dysbiosis in intestinal inflammation: Cause or consequence. Int. J. Med Microbiol. 2016, 306, 302-309
50. Buttó, L.F.; Schaubeck, M.; Haller, D. Mechanisms of microbehost interaction in Crohn’s disease: Dysbiosis vs pathobiont selection. Front. Immunol. 2015, 6, 1-20
51. Lepage, P.; Häsler, R.; Spehlmann, M.E.; Rehman, A.; Zvirbliene, A.; Begun, A.; Ott, S.; Kupcinskas, L.; Doré, J.; Raedler, A. et al. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology 2011, 141, 227-236
52. Willing, B.P.; Dicksved, J.; Halfvarson, J.; Andersson, A.F.; Lucio, M.; Zheng, Z.; Järnerot, G.; Tysk, C.; Jansson, J.K.; Engstrand, L. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 2010, 139, 1844-1854
53. Zeng, M.Y.; Inohara, N.; Nuñez, G. Mechanisms of inflammation-driven bacterial dysbiosis in the gut. Mucosal Immunol. 2017, 10, 18-26
54. Ohata, A.; Usami, M.; Miyoshi, M. Short-chain fatty acids alter tight junction permeability in intestinal monolayer cells via lipoxygenase activation. Nutrition 2005, 21, 838-847
55. Vinolo, M.A.; Ferguson, G.J.; Kulkarni, S.; Damoulakis, G.; Anderson, K.; Bohlooly, Y. M.; Stephens, L.; Hawkins, P.T.; Curi, R. SCFAs induce mouse neutrophil chemotaxis through the GPR43 receptor. PLoS ONE 2011, 6, e21205
56. Canfora, E.E.; Jocken, J.W.; Blaak, E.E. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat. Rev. Endocrinol. 2015, 11, 577-591
57. Schirmer, M.; Smeekens, S.P.; Vlamakis, H.; Jaeger, M.; Oosting, M.; Franzosa, E.A.; ter Horst, R.; Jansen, T.; Jacobs, L.; Bonder, M.J. et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell 2016, 167, 1125-1136
58. Luo, A.; Leach, S.T.; Barres, R.; Hesson, L.B.; Grimm, M.C.; Simar, D. The microbiota and epigenetic regulation of T helper 17/regulatory T cells: In search of a balanced immune system. Front. Immunol. 2017, 8, 417
59. Swidsinski, A.; Loening-Baucke, V.; Verstraelen, H.; Osowska, S.; Doerffel, Y. Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology 2008, 135, 568-579
60. Abu-Shanab, A.; Quigley, E.M. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 2010, 7, 691-701
61. Adams, J.B.; Johansen, L.J.; Powell, L.D.; Quig, D.; Rubin, R.A. Gastrointestinal flora and gastrointestinal status in children with autism-comparisons to typical children and correlation with autism severity. BMC Gastroenterol. 2011, 11, 22
62. Kamada, N.; Seo, S.U.; Chen, G.Y.; Núñez, G. Role of the gut microbiota in immunity and inflammatory disease. Nat. Rev. Immunol. 2013, 13, 321-325
63. Le Chatelier, E.; Nielsen, T.; Qin, J.; Prifti, E.; Hildebrand, F.; Falony, G.; Almeida, M.; Arumugam, M.; Batto, J.M.; Kennedy, S. Richness of human gut microbiome correlates with metabolic markers. Nature 2013, 500, 541-546
64. Ridaura, V.K.; Faith, J.J.; Rey, F.E.; Cheng, J.; Duncan, A.E.; Kau, A.L.; Griffin, N.W.; Lombard, V.; Henrissat, B.; Bain, J.R. et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013, 341, 1241214
65. Schwabe, R.F.; Jobin, C. The microbiome and cancer. Nat. Rev. Cancer 2013, 13, 800-812
66. Serino, M.; Blasco-Baque, V.; Nicolas, S.; Burcelin, R. Far from the eyes, close to the heart: Dysbiosis of gut microbiota and cardiovascular consequences. Curr. Cardiol. Rep. 2014, 16, 540
67. Kostic, A.D.; Gevers, D.; Siljander, H.; Vatanen, T.; Hyötyläinen, T.; Hämäläinen, A.M.; Peet, A.; Tillmann, V.; Pöhö, P.; Mattila, I. et al. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. Cell Host Microbe 2015, 17, 260-273
68. Casen, C.; Vebø, H.C.; Sekelja, M.; Hegge, F.T.; Karlsson, M.K.; Ciemniejewska, E.; Dzankovic, S.; Frøyland, C.; Nestestog, R.; Engstrand, L. et al. Deviations in human gut microbiota: A novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment. Pharmacol. Ther. 2015, 42, 71-83
69. Wright, E.K.; Kamm, M.A.; Teo, S.M.; Inouye, M.; Wagner, J.; Kirkwood, C.D. Recent advances in characterizing the gastrointestinal microbiome in Crohn’s disease: A systematic review. Inflamm. Bowel Dis. 2015, 21, 1219-1228
70. Huttenhower, C.; Kostic, A.D.; Xavier, R.J. Inflammatory bowel disease as a model for translating the microbiome. Immunity 2014, 40, 843-854
71. Walker, A.W.; Sanderson, J.D.; Churcher, C.; Parkes, G.C.; Hudspith, B.N.; Rayment, N.; Brostoff, J.; Parkhill, J.; Dougan, G.; Petrovska, L. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 2011, 11, 7
72. Marchesi, J.R.; Holmes, E.; Khan, F.; Kochhar, S.; Scanlan, P.; Shanahan, F.; Wilson, I.D.; Wang, Y. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J. Proteome Res. 2007, 6, 546-551
73. Zhang, M.; Liu, B.; Zhang, Y.; Wei, H.; Lei, Y.; Zhao, L. Structural shifts of mucosa-associated lactobacilli and Clostridium leptum subgroup in patients with ulcerative colitis. J. Clin. Microbiol. 2007, 45, 496-500
74. Tamboli, C.P.; Neut, C.; Desreumaux, P.; Colombel, J.F. Dysbiosis in inflammatory bowel disease. Gut 2004, 53, 1-4
75. Kostic, A.D.; Xavier, R.J.; Gevers, D. The microbiome in inflammatory bowel disease: Current status and the future ahead. Gastroenterology 2014, 146, 1489-1499
76. Nagalingam, N.A.; Lynch, S.V. Role of the microbiota in inflammatory bowel diseases. Inflamm. Bowel Dis. 2011, 18, 968-984
77. Mondot, S.; Kang, S.; Furet, J.P.; Aguirre de Cárcer, D.; McSweeney, C.; Morrison, M.; Marteau, P.; Dore, J.; Leclerc, M. Highlighting new phylogenetic specificities of Crohn’s disease microbiota. Inflamm. Bowel Dis. 2010, 17, 185-192
78. Hedin, C.R.; McCarthy, N.E.; Louis, P.; Farquharson, F.M.; McCartney, S.; Taylor, K.; Prescott, N.J.; Murrells, T.; Stagg, A.J.; Whelan, K. et al. Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn’s disease and their unaffected siblings. Gut 2014, 63, 1578-1586
79. Nguyen, G.C. Bugs and drugs: Insights into the pathogenesis of inflammatory bowel disease. Am. J. Gastroenterol. 2011, 106, 2143-2145
80. Bien, J.; Palagani, V.; Bozko, P. The intestinal microbiota dysbiosis and Clostridium difficile infection: Is there a relationship with inflammatory bowel disease? Ther. Adv. Gastroenterol. 2013, 6, 53-68
81. Li, J.; Butcher, J.; Mack, D.; Stintzi, A. Functional impacts of the intestinal microbiome in the pathogenesis of inflammatory bowel disease. Inflamm. Bowel Dis. 2014, 21, 139-153
82. Joossens, M.; Huys, G.; Cnockaert, M.; De Preter, V.; Verbeke, K.; Rutgeerts, P.; Vandamme, P.; Vermeire, S. Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives. Gut 2011, 60, 631-637
83. Gevers, D.; Kugathasan, S.; Denson, L.A.; Vázquez-Baeza, Y.; Van Treuren, W.; Ren, B.; Morgan, X.C. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 2014, 15, 382-392
84. Macpherson, A.J.; Gatto, D.; Sainsbury, E.; Harriman, G.R.; Hengartner, H.; Zinkernagel, R.M. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science 2000, 288, 2222-2226
85. Sartor, R.B. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008, 134, 577-594
86. Nemoto, H.; Kataoka, K.; Ishikawa, H.; Ikata, K.; Arimochi, H.; Iwasaki, T.; Yasutomo, K. Reduced diversity and imbalance of fecal microbiota in patients with ulcerative colitis. Dig. Dis. Sci. 2012, 57, 2955-2964
87. Sha, S.; Xu, B.; Wang, X.; Zhang, Y.; Wang, H.; Kong, X.; Wu, K. The biodiversity and composition of the dominant fecal microbiota in patients with inflammatory bowel disease. Diagn. Microbiol. Infect. Dis. 2013, 75, 245-251
88. Schultsz, C.; van den Berg, F.M.; Fiebo, W.; Tytgat, G.N.; Dankert, J. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology 1999, 117, 1089-1097
89. Manichanh, C.; Rigottier-Gois, L.; Bonnaud, E.; Gloux, K.; Pelletier, E.; Frangeul, L.; Nalin, R.; Jarrin, C.; Chardon, P.; Marteau, P. et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut 2006, 55, 205-211
90. Lloyd-Price, J.; Arze, C.; Ananthakrishnan, A.N.; Schirmer, M.; Avila-Pacheco, J.; Poon, T.W.; Andrews, E.; Ajami, N.J.; Bonham, K.S.; Brislawn, C.J. et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature 2019, 569, 655
91. Yilmaz, B.; Juillerat, P.; Øyås, O.; Ramon, C.; Bravo, F.D.; Franc, Y.; Fournier, N.; Michetti, P.; Mueller, C.; Geuking, M. et al. Microbial network disturbances in relapsing refractory Crohn’s disease. Nat. Med. 2019, 25, 323
92. Brown, E.M.; Wlodarska, M.; Willing, B.P.; Vonaesch, P.; Han, J.; Reynolds, L.A.; Arrieta, M.C.; Uhrig, M.; Scholz, R.; Partida, O. et al. Diet and specific microbial exposure trigger features of environmental enteropathy in a novel murine model. Nat. Commun. 2015, 6, 7806
93. Keely, S.; Walker, M.M.; Marks, E.; Talley, N.J. Immune dysregulation in the functional gastrointestinal disorders. Eur. J. Clin. Investig. 2015, 45, 1350-1359
94. D’argenio, V.; Casaburi, G.; Precone, V.; Pagliuca, C.; Colicchio, R.; Sarnataro, D.; Discepolo, V.; Kim, S.M.; Russo, I.; Blanco, G.D.V. et al. Metagenomics reveals dysbiosis and a potentially pathogenic N. flavescens strain in duodenum of adult celiac patients. Am. J. Gastroenterol. 2016, 111, 879
95. Distrutti, E.; Monaldi, L.; Ricci, P.; Fiorucci, S. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World J. Gastroenterol. 2016, 22, 2219-2241
96. Larcombe, S.; Hutton, M.L.; Lyras, D. Involvement of bacteria other than Clostridium difficile in antibiotic-associated diarrhoea. Trends Microbiol. 2016, 24, 463-476
97. Matsuoka, K.; Kanai, T. The gut microbiota and inflammatory bowel disease. Semin. Immunopathol. 2015, 37, 47-55
98. Bibiloni, R.; Mangold, M.; Madsen, K.L.; Fedorak, R.N.; Tannock, G.W. The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn’s disease and ulcerative colitis patients. J. Med. Microbiol. 2006, 55, 1141-1149
99. Rath, H.C.; Herfarth, H.H.; Ikeda, J.S.; Grenther, W.B.; Hamm, T.E.; Balish, E.; Taurog, J.D.; Hammer, R.E.; Wilson, K.H.; Sartor, R.B. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J. Clin. Investig. 1996, 98, 945-953
100. Sellon, R.K.; Tonkonogy, S.; Schultz, M.; Dieleman, L.A.; Grenther, W.; Balish, E.; Rennick, D.M.; Sartor, R.B. Resident enteric bacteria are necessary for the development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect. Immun. 1998, 66, 5224-5231
101. Strober, W.; Fuss, I.; Mannon, P. The fundamental basis of inflammatory bowel disease. J. Clin. Investig. 2007, 117, 514-521
102. Taurog, J.D.; Richardson, J.A.; Croft, J.T.; Simmons, W.A.; Zhou, M.; Fernández-Sueiro, J.L.; Balish, E.; Hammer, R.E. The germ free state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J. Exp. Med. 1994, 180, 2359-2364
103. Veltkamp, C.; Tonkonogy, S.L.; De Jong, Y.P.; Albright, C.; Grenther, W.B.; Balish, E.; Terhorst, C.; Sartor, R.B. Continuous stimulation by normal luminal bacteria is essential for the development and perpetuation of colitis in Tgϵ26 mice. Gastroenterology 2001, 120, 900-913
104. Pils, M.C.; Bleich, A.; Prinz, I.; Fasnacht, N.; Bollati-Fogolin, M.; Schippers, A.; Rozell, B.; Müller, W. Commensal gut flora reduces susceptibility to experimentally induced colitis via T-cell-derived interleukin-10. Inflamm. Bowel Dis. 2010, 17, 2038-2046
105. Yang, I.; Eibach, D.; Kops, F.; Brenneke, B.; Woltemate, S.; Schulze, J.; Bleich, A.; Gruber, A.D.; Muthupalani, S.; Fox, J.G. et al. Intestinal microbiota composition of interleukin-10 deficient C57BL/6J mice and susceptibility to Helicobacter hepaticus-induced colitis. PLoS ONE 2013, 8, e70783
106. Garrett, W.S.; Lord, G.M.; Punit, S.; Lugo-Villarino, G.; Mazmanian, S.K.; Ito, S.; Glickman, J.N.; Glimcher, L.H. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 2007, 131, 33-45
107. Ott, S.J.; Waetzig, G.H.; Rehman, A.; Moltzau-Anderson, J.; Bharti, R.; Grasis, J.A.; Cassidy, L.; Tholey, A.; Fickenscher, H.; Seegert, D. et al. Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile infection. Gastroenterology 2017, 152, 799-811
108. Moayyedi, P.; Surette, M.G.; Kim, P.T.; Libertucci, J.; Wolfe, M.; Onischi, C.; Armstrong, D.; Marshall, J.K.; Kassam, Z.; Reinisch, W. et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015, 149, 102-109
109. Rioux, K.P.; Fedorak, R.N. Probiotics in the treatment of inflammatory bowel disease. J. Clin. Gastroenterol. 2006, 40, 260-263
110. Bengmark, S. Bioecological control of inflammatory bowel disease. Clin. Nutr. 2007, 26, 169181
111. Roberfroid, M. Prebiotics: The concept revisited. J. Nutr. 2007, 137, 830-837
112. Bengmark, S. Pre-, pro-and synbiotics. Curr. Opin. Clin. Nutr. Metab. Care 2001, 4, 571-579
113. Gionchetti, P.; Rizzello, F.; Helwig, U.; Venturi, A.; Lammers, K.M.; Brigidi, P.; Vitali, B.; Poggioli, G.; Miglioli, M.; Campieri, M. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology 2003, 124, 1202-1209
114. Perencevich, M.; Burakoff, R. Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm. Bowel Dis. 2006, 12, 651-664
115. Damaskos, D.; Kolios, G. Probiotics and prebiotics in inflammatory bowel disease: Microflora ‘on the scope’. Br. J. Clin. Pharmacol. 2008, 65, 453-467
116. Matijašić, M.; Meštrović, T.; Perić, M.; Čipčić Paljetak, H.; Panek, M.; Vranešić Bender, D.; Ljubas Kelečić, D.; Krznarić, Ž.; Verbanac, D. Modulating composition and metabolic activity of the gut microbiota in IBD patients. Int. J. Mol. Sci. 2016, 17, 578
117. Forbes, J.D.; Van Domselaar, G.; Bernstein, C.N. The gut microbiota in immune-mediated inflammatory diseases. Front. Microbiol. 2016, 7, 1081
118. Nell, S.; Suerbaum, S.; Josenhans, C. The impact of the microbiota on the pathogenesis of IBD: Lessons from mouse infection models. Nat. Rev. Microbiol. 2010, 8, 564-567
119. Rhee, K.J.; Wu, S.; Wu, X.; Huso, D.L.; Karim, B.; Franco, A.A.; Rabizadeh, S.; Golub, J.E.; Mathews, L.E.; Shin, J. et al. Induction of persistent colitis by a human commensal, enterotoxigenic Bacteroides fragilis, in wild-type C57BL/6 mice. Infect. Immun. 2009, 77, 1708-1718
120. Hold, G.L.; Smith, M.; Grange, C.; Watt, E.R.; El-Omar, E.M.; Mukhopadhya, I. Role of the gut microbiota in inflammatory bowel disease pathogenesis: What have we learnt in the past 10 years? World J. Gastroenterol. WJG 2014, 20, 1192-1210
121. Nataro, J.P.; Kaper, J.B. Diarrheagenic escherichia coli. Clin. Microbiol. Rev. 1998, 11, 142-201
122. Simpson, K.W.; Dogan, B.; Rishniw, M.; Goldstein, R.E.; Klaessig, S.; McDonough, P.L.; German, A.J.; Yates, R.M.; Russell, D.G.; Johnson, S.E. et al. Adherent and invasive Escherichia coli is associated with granulomatous colitis in boxer dogs. Infect. Immun. 2006, 74, 4778-4792
123. Darfeuille-Michaud, A.; Neut, C.; Barnich, N.; Lederman, E.; Di Martino, P.; Desreumaux, P.; Gambiez, L.; Joly, B.; Cortot, A.; Colombel, J.F. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn’s disease. Gastroenterology 1998, 115, 1405-1413
124. Martinez-Medina, M.; Aldeguer, X.; Lopez-Siles, M.; González-Huix, F.; López-Oliu, C.; Dahbi, G.; Blanco, J.E.; Blanco, J.; Garcia-Gil, J.L.; Darfeuille-Michaud, A. Molecular diversity of Escherichia coli in the human gut: New ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohn’s disease. Inflamm. Bowel Dis. 2009, 15, 872-882
125. Mann, E.A.; Saeed, S.A. Gastrointestinal infection as a trigger for inflammatory bowel disease. Curr. Opin. Gastroenterol. 2012, 28, 24-29
126. Pierce, E.S. Ulcerative colitis and Crohn’s disease: Is Mycobacterium aviumsubspecies paratuberculosis the common villain? Gut Pathog. 2010, 2, 21
127. Elguezabal, N.; Chamorro, S.; Molina, E.; Garrido, J.M.; Izeta, A.; Rodrigo, L.; Juste, R.A. Lactase persistence, NOD2 status and Mycobacterium avium subsp. paratuberculosis infection associations to Inflammatory Bowel Disease. Gut Pathog.2012, 4, 6
128. Kirkwood, C.D.; Wagner, J.; Boniface, K.; Vaughan, J.; Michalski, W.P.; Catto-Smith, A.G.; Cameron, D.J.; Bishop, R.F. Mycobacterium avium subspecies paratuberculosis in children with early onset Crohn’s disease. Inflamm. Bowel Dis. 2009, 15, 1643-1655
129. Naser, S.A.; Ghobrial, G.; Romero, C.; Valentine, J.F. Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn’s disease. Lancet 2004, 364, 1039-1044
130. Sanderson, J.D.; Moss, M.T.; Tizard, M.L.; Hermon-Taylor, J. Mycobacterium paratuberculosis DNA in Crohn’s disease tissue. Gut 1992, 33, 890-896
131. Friswell, M.; Campbell, B.; Rhodes, J. The role of bacteria in the pathogenesis of inflammatory bowel disease. Gut Liver 2010, 4, 295-306
132. Ferwerda, G.; Girardin, S.E.; Kullberg, B.J.; Le Bourhis, L.; De Jong, D.J.; Langenberg, D.M.; Van Crevel, R.; Adema, G.J.; Ottenhoff, T.H.; Van der Meer, J.W. NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathog. 2005, 1, e34
133. Ferwerda, G.; Kullberg, B.J.; De Jong, D.J.; Girardin, S.E.; Langenberg, D.M.; Van Crevel, R.; Ottenhoff, T.H.; Van der Meer, J.W.; Netea, M.G. Mycobacterium paratuberculosis is recognized by Toll-like receptors and NOD2. J. Leukoc. Biol.2007, 82, 1011-1018
134. Gutierrez, M.G.; Master, S.S.; Singh, S.B.; Taylor, G.A.; Colombo, M.I.; Deretic, V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004, 119, 753-766
135. Hansen, R.; Thomson, J.M.; El-Omar, E.M.; Hold, G.L. The role of infection in the aetiology of inflammatory bowel disease. J. Gastroenterol. 2010, 45, 266-276
136. Juste, R.A.; Elguezabal, N.; Garrido, J.M.; Pavon, A.; Geijo, M.V.; Sevilla, I.; Cabriada, J.L.; Tejada, A.; García-Campos, F.; Casado, R. et al. On the prevalence of M. avium subspecies paratuberculosis DNA in the blood of healthy individuals and patients with inflammatory bowel disease. PLoS ONE 2008, 3, e2537
137. Selby, W.; Pavli, P.; Crotty, B.; Florin, T.; Radford-Smith, G.; Gibson, P.; Mitchell, B.; Connell, W.; Read, R.; Merrett, M. et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn’s disease. Gastroenterology 2007, 132, 2313-2319
138. Navaneethan, U.; Venkatesh, P.G.; Shen, B. Clostridium difficile infection and inflammatory bowel disease: Understanding the evolving relationship. World J. Gastroenterol. WJG 2010, 16, 4892-4904
139. Kim, H.; Rhee, S.H.; Pothoulakis, C.; LaMont, J.T. Inflammation and apoptosis in Clostridium difficile enteritis is mediated by PGE2 up-regulation of Fas ligand. Gastroenterology 2007, 133, 875-886
140. Issa, M.; Vijayapal, A.; Graham, M.B.; Beaulieu, D.B.; Otterson, M.F.; Lundeen, S.; Skaros, S.; Weber, L.R.; Komorowski, R.A.; Knox, J.F. et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2007, 5, 345-351
141. Fujimoto, T.; Imaeda, H.; Takahashi, K.; Kasumi, E.; Bamba, S.; Fujiyama, Y.; Andoh, A. Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of C rohn’s disease. J. Gastroenterol. Hepatol. 2013, 28, 613-619
142. Fava, F.; Danese, S. Intestinal microbiota in inflammatory bowel disease: Friend of foe? World J. Gastroenterol. WJG 2011, 17, 557
143. Seksik, P.; Rigottier-Gois, L.; Gramet, G.; Sutren, M.; Pochart, P.; Marteau, P.; Jian, R.; Dore, J. Alterations of the dominant faecal bacterial groups in patients with Crohn’s disease of the colon. Gut 2003, 52, 237-242
144. Favier, C.; Neut, C.; Mizon, C.; Cortot, A.; Colombel, J.F.; Mizon, J. Fecal β-D-galactosidase production and Bifidobacteria are decreased in Crohn’s disease. Dig. Dis. Sci. 1997, 42, 817-822
145. Bartels, L.E.; Jepsen, P.; Christensen, L.A.; Gerdes, L.U.; Vilstrup, H.; Dahlerup, J.F. Diagnosis of Helicobacter pylori infection is associated with lower prevalence and subsequent incidence of Crohn’s disease. J. Crohn’s Colitis 2015, 10, 443-448
146. McMullen, L.; Leach, S.T.; Lemberg, D.A.; Day, A.S. Current roles of specific bacteria in the pathogenesis of inflammatory bowel disease. Microbiology 2015, 1, 82-91
147. Zhang, L.; Lee, H.; Grimm, M.C.; Riordan, S.M.; Day, A.S.; Lemberg, D.A. Campylobacter concisus and inflammatory bowel disease. World J. Gastroenterol. WJG 2014, 20, 1259-1267
148. Martin, H.M.; Campbell, B.J.; Hart, C.A.; Mpofu, C.; Nayar, M.; Singh, R.; Englyst, H.; Williams, H.F.; Rhodes, J.M. Enhanced Escherichia coli adherence and invasion in Crohn’s disease and colon cancer 1. Gastroenterology 2004, 127, 80-93
149. De Hertogh, G.; Aerssens, J.; Geboes, K.P.; Geboes, K. Evidence for the involvement of infectious agents in the pathogenesis of Crohn’s disease. World J. Gastroenterol. WJG 2008, 14, 845
150. Pascal, V.; Pozuelo, M.; Borruel, N.; Casellas, F.; Campos, D.; Santiago, A.; Martinez, X.; Varela, E.; Sarrabayrouse, G.; Machiels, K. et al. A microbial signature for Crohn’s disease. Gut 2017, 66, 813-822
151. Sokol, H.; Lay, C.; Seksik, P.; Tannock, G.W. Analysis of bacterial bowel communities of IBD patients: What has it revealed? Inflamm. Bowel Dis. 2008, 14, 858-867
152. Santoru, M.L.; Piras, C.; Murgia, A.; Palmas, V.; Camboni, T.; Liggi, S.; Ibba, I.; Lai, M.A.; Orrù, S.; Blois, S. et al. Cross sectional evaluation of the gut-microbiome metabolome axis in an Italian cohort of IBD patients. Sci. Rep. 2017, 7, 9523
153. Vrakas, S.; Mountzouris, K.C.; Michalopoulos, G.; Karamanolis, G.; Papatheodoridis, G.; Tzathas, C.; Gazouli, M. Intestinal bacteria composition and translocation of bacteria in inflammatory bowel disease. PLoS ONE 2017, 12, e0170034
154. Walters, S.S.; Quiros, A.; Rolston, M.; Grishina, I.; Li, J.; Fenton, A.; DeSantis, T.Z.; Thai, A.; Andersen, G.L.; Papathakis, P. et al. Analysis of gut microbiome and diet modification in patients with Crohn’s disease. SOJ Microbiol. Infect. Dis. 2014, 2, 1
155. Jacobs, J.P.; Goudarzi, M.; Singh, N.; Tong, M.; McHardy, I.H.; Ruegger, P.; Asadourian, M.; Moon, B.H.; Ayson, A.; Borneman, J. et al. Adisease-associated microbial and metabolomics state in relatives of pediatric inflammatory bowel disease patients. Cell. Mol. Gastroenterol. Hepatol. 2016, 2, 750-766
156. Morgan, X.C.; Tickle, T.L.; Sokol, H.; Gevers, D.; Devaney, K.L.; Ward, D.V.; Reyes, J.A.; Shah, S.A.; LeLeiko, N.; Snapper, S.B. et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012, 13, 79
157. Ott, S.J.; Musfeldt, M.; Wenderoth, D.F.; Hampe, J.; Brant, O.; Fölsch, U.R.; Timmis, K.N.; Schreiber, S. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004, 53, 685-693
158. Verma, R.; Verma, A.K.; Ahuja, V.; Paul, J. Real-time analysis of mucosal flora in patients with inflammatory bowel disease in India. J. Clin. Microbiol. 2010, 48, 4279-4282
159. Halfvarson, J.; Brislawn, C.J.; Lamendella, R.; Vázquez-Baeza, Y.; Walters, W.A.; Bramer, L.M.; D’amato, M.; Bonfiglio, F.; McDonald, D.; Gonzalez, A. et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat. Microbiol. 2017, 2, 17004
160. Scaldaferri, F.; Gerardi, V.; Lopetuso, L.R.; Del Zompo, F.; Mangiola, F.; Boškoski, I.; Bruno, G.; Petito, V.; Laterza, L.; Cammarota, G. et al. Gut microbial flora, prebiotics, and probiotics in IBD: Their current usage and utility. BioMed Res. Int. 2013, 2013, 9
161. Machiels, K.; Joossens, M.; Sabino, J.; De Preter, V.; Arijs, I.; Eeckhaut, V.; Ballet, V.; Claes, K.; Van Immerseel, F.; Verbeke, K. et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 2014, 63, 1275-1283
162. Wang, W.; Chen, L.; Zhou, R.; Wang, X.; Song, L.; Huang, S.; Wang, G.; Xia, B. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J. Clin. Microbiol. 2014, 52, 398-406
163. De Filippo, C.; Cavalieri, D.; Di Paola, M.; Ramazzotti, M.; Poullet, J.B.; Massart, S.; Collini, S.; Pieraccini, G.; Lionetti, P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl. Acad. Sci. USA 2010, 107, 14691-14696
164. Tong, M.; Li, X.; Parfrey, L.W.; Roth, B.; Ippoliti, A.; Wei, B.; Borneman, J.; McGovern, D.P.; Frank, D.N.; Li, E. A modular organization of the human intestinal mucosal microbiota and its association with inflammatory bowel disease. PLoS ONE 2013, 8, e80702
165. Okayasu, I.; Hatakeyama, S.; Yamada, M.; Ohkusa, T.; Inagaki, Y.; Nakaya, R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990, 98, 694-702
166. Håkansson, Å.; Tormo-Badia, N.; Baridi, A.; Xu, J.; Molin, G.; Hagslätt, M.L.; Karlsson, C.; Jeppsson, B.E.N.G.T.; Cilio, C.M.; Ahrné, S. Immunological alteration and changes of gut microbiota after dextran sulfate sodium (DSS) administration in mice. Clin. Exp. Med. 2015, 15, 107-120
167. Ettreiki, C.; Gadonna-Widehem, P.; Mangin, I.; Coëffier, M.; Delayre-Orthez, C.; Anton, P.M. Juvenile ferric iron prevents microbiota dysbiosis and colitis in adult rodents. World J. Gastroenterol. WJG 2012, 18, 2619-2629
168. Rooks, M.G.; Veiga, P.; Wardwell-Scott, L.H.; Tickle, T.; Segata, N.; Michaud, M.; Gallini, C.A.; Beal, C.; van Hylckama-Vlieg, J.E.; Ballal, S.A. et al. Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission. ISME J. 2014, 8, 1403-1417
169. Nagao-Kitamoto, H.; Shreiner, A.B.; Gillilland, M.G., 3rd; Kitamoto, S.; Ishii, C.; Hirayama, A.; Kuffa, P.; El-Zaatari, M.; Grasberger, H.; Seekatz, A.M. et al. Functional characterization of inflammatory bowel disease-associated gut dysbiosis in gnotobiotic mice. Cell. Mol. Gastroenterol. Hepatol. 2016, 2, 468-481
170. Arthur, J.C.; Perez-Chanona, E.; Mühlbauer, M.; Tomkovich, S.; Uronis, J.M.; Fan, T.J.; Campbell, B.J.; Abujamel, T.; Dogan, B.; Rogers, A.B. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012, 338, 120-123
171. Dennis, K.L.; Wang, Y.; Blatner, N.R.; Wang, S.; Saadalla, A.; Trudeau, E.; Roers, A.; Weaver, C.T.; Lee, J.J.; Gilbert, J.A. et al. Adenomatous polyps are driven by microbe-instigated focal inflammation and are controlled by IL-10-producing T cells. Cancer Res. 2013, 73, 5905-5913
172. Jostins, L.; Ripke, S.; Weersma, R.K.; Duerr, R.H.; McGovern, D.P.; Hui, K.Y.; Lee, J.C.; Schumm, L.P.; Sharma, Y.; Anderson, C.A. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491, 119-124
173. Duerr, R.H.; Taylor, K.D.; Brant, S.R.; Rioux, J.D.; Silverberg, M.S.; Daly, M.J.; Steinhart, A.H.; Abraham, C.; Regueiro, M.; Griffiths, A. et al. A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene. Science 2006, 314, 1461-1463
174. A Fisher, S.; Tremelling, M.; A Anderson, C.; Gwilliam, R.; Bumpstead, S.; Prescott, N.J.; Nimmo, E.R.; Massey, D.; Berzuini, C.; Johnson, C. et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn’s disease. Nat. Genet. 2008, 40, 710-712
175. Hugot, J.P.; Chamaillard, M.; Zouali, H.; Lesage, S.; Cézard, J.P.; Belaiche, J.; Almer, S.; Tysk, C.; O’Morain, C.A.; Gassull, M. et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001, 411, 599-603
176. Ogura, Y.; Bonen, D.K.; Inohara, N.; Nicolae, D.L.; Chen, F.F.; Ramos, R.; Britton, H.; Moran, T.; Karaliuskas, R.; Duerr, R.H. et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001, 411, 603-606
177. Tanabe, T.; Chamaillard, M.; Ogura, Y.; Zhu, L.; Qiu, S.; Masumoto, J.; Ghosh, P.; Moran, A.; Predergast, M.M.; Tromp, G. et al. Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition. EMBO J. 2004, 23, 1587-1597
178. Ogura, Y.; Inohara, N.; Benito, A.; Chen, F.F.; Yamaoka, S.; Núñez, G. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-κB. J. Biol. Chem. 2001, 276, 4812-4818
179. Watanabe, T.; Kitani, A.; Murray, P.J.; Strober, W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat. Immunol. 2004, 5, 800-808
180. Wehkamp, J.; Salzman, N.H.; Porter, E.; Nuding, S.; Weichenthal, M.; Petras, R.E.; Shen, B.; Schaeffeler, E.; Schwab, M.; Linzmeier, R. et al. Reduced Paneth cell α-defensins in ileal Crohn’s disease. Proc. Natl. Acad. Sci. USA 2005, 102, 18129-18134
181. Petnicki-Ocwieja, T.; Hrncir, T.; Liu, Y.-J.; Biswas, A.; Hudcovic, T.; Tlaskalova-Hogenova, H.; Kobayashi, K.S. Nod2 is required for the regulation of commensal microbiota in the intestine. Proc. Natl. Acad. Sci. USA 2009, 106, 15813-15818
182. Frank, D.N.; Robertson, C.E.; Hamm, C.M.; Kpadeh, Z.; Zhang, T.; Chen, H.; Zhu, W.; Sartor, R.B.; Boedeker, E.C.; Harpaz, N. et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm. Bowel Dis. 2010, 17, 179-184
183. Li, E.; Hamm, C.M.; Gulati, A.S.; Sartor, R.B.; Chen, H.; Wu, X.; Zhang, T.; Rohlf, F.J.; Zhu, W.; Gu, C. et al. Inflammatory Bowel Diseases Phenotype, C. difficile and NOD2 Genotype Are Associated with Shifts in Human Ileum Associated Microbial Composition. PLoS ONE 2012, 7, e26284
184. Couturier-Maillard, A.; Secher, T.; Rehman, A.; Normand, S.; De Arcangelis, A.; Häesler, R.; Huot, L.; Grandjean, T.; Bressenot, A.; Delanoye-Crespin, A. et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J. Clin. Investig. 2013, 123, 700-711
185. Rehman, A.; Sina, C.; Gavrilova, O.; Häsler, R.; Ott, S.; Baines, J.F.; Schreiber, S.; Rosenstiel, P. Nod2 is essential for temporal development of intestinal microbial communities. Gut 2011, 60, 1354-1362
186. Hampe, J.; Franke, A.; Rosenstiel, P.; Till, A.; Teuber, M.; Huse, K.; Albrecht, M.; Mayr, G.; De La Vega, F.M.; Briggs, J. et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet. 2007, 39, 207-211
187. Cadwell, K.; Liu, J.Y.; Brown, S.L.; Miyoshi, H.; Loh, J.; Lennerz, J.K.; Kishi, C.; Kc, W.; Carrero, J.A.; Hunt, S. et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 2008, 456, 259-263
188. Gunther, C.; Martini, E.; Wittkopf, N.; Amann, K.; Weigmann, B.; Neumann, H.; Waldner, M.J.; Hedrick, S.M.; Tenzer, S.; Neurath, M.F. et al. Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis. Nature 2011, 477, 335-339
189. Ward, J.M.; Anver, M.R.; Haines, D.C.; Melhorn, J.M.; Gorelick, P.; Yan, L.; Fox, J.G. Imflammatory large bowel disease in immunodeficient mice naturally infected with. Helicobacter hepaticus. Lab. Anim. Sci. 1996, 46, 15-20
190. Cerf-Bensussan, N.; Gaboriau-Routhiau, V. The immune system and the gut microbiota: Friends or foes? Nat. Rev. Immunol. 2010, 10, 735-744
191. 4+ T regulatory cells suppress Helicobacter hepaticus-induced colitis. J. Exp. Med. 2002, 196, 505-515
192. Cadwell, K.; Patel, K.K.; Maloney, N.S.; Liu, T.-C.; Ng, A.C.; Storer, C.E.; Head, R.D.; Xavier, R.; Stappenbeck, T.S.; Virgin, H.W. Virus-Plus-Susceptibility Gene Interaction Determines Crohn’s Disease Gene Atg16L1 Phenotypes in Intestine. Cell 2010, 141, 1135-1145
193. Nenci, A.; Becker, C.; Wullaert, A.; Gareus, R.; Van Loo, G.; Danese, S.; Huth, M.; Nikolaev, A.; Neufert, C.; Madison, B. et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2007, 446, 557-561
194. Rossi, M.; Corradini, C.; Amaretti, A.; Nicolini, M.; Pompei, A.; Zanoni, S.; Matteuzzi, D. Fermentation of Fructooligosaccharides and Inulin by Bifidobacteria: A Comparative Study of Pure and Fecal Cultures. Appl. Environ. Microbiol. 2005, 71, 6150-6158
195. Bensoussan, M.; Jovenin, N.; Garcia, B.; Vandromme, L.; Jolly, D.; Bouché, O.; Thiéfin, G.; Cadiot, G. Complementary and alternative medicine use by patients with inflammatory bowel disease: Results from a postal survey. Gastroentérol. Clin. Biol. 2006, 30, 14-23
196. Langhorst, J.; Anthonisen, I.B.; Steder-Neukamm, U.; Lüdtke, R.; Spahn, G.; Michalsen, A.; Dobos, G.J. Amount of Systemic Steroid Medication Is a Strong Predictor for the Use of Complementary and Alternative Medicine in Patients With Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2005, 11, 287-295
197. Hilsden, R.J.; Verhoef, M.J.; Best, A.; Pocobelli, G. Complementary and alternative medicine use by Canadian patients with inflammatory bowel disease: Results from a national survey. Am. J. Gastroenterol. 2003, 98, 1563-1568
198. Rahimi, R.; Mozaffari, S.; Abdollahi, M. On the use of herbal medicines in management of inflammatory bowel diseases: A systematic review of animal and human studies. Dig. Dis. Sci. 2009, 54, 471-480
199. Lukovac, S.; Belzer, C.; Pellis, L.; Keijser, B.J.; De Vos, W.M.; Montijn, R.C.; Roeselers, G. Differential Modulation by Akkermansia muciniphila and Faecalibacterium prausnitzii of Host Peripheral Lipid Metabolism and Histone Acetylation in Mouse Gut Organoids. mBio 2014, 5, e01438-14
200. Abraham, C.; Cho, J.H. Inflammatory bowel disease. N. Engl. J. Med. 2009, 361, 2066-2078
201. World Health Organization. General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine; No. WHO/EDM/TRM/2000.1; World Health Organization: Geneva, Swizterland, 2000
202. Zhang, J.; Bai, G. Wumei pill decoction in the treatment of 72 cases of chronic nonspecific ulcerative colitis. Mod. J. Integr. Tradit. West. Med. 2007, 16, 5156-5157
203. Foley, M.H.; Cockburn, D.W.; Koropatkin, N.M. The Sus operon: A model system for starch uptake by the human gut Bacteroidetes. Cell. Mol. Life Sci. 2016, 73, 2603-2617
204. Liang, J.H.; Zheng, K.W.; Sun, L.Q. Explore the regulative action of astragalus polysaccharide for intestinal dysbacteriosis in ulcerative colitis rat models. Stud. Trace Elem. Health. 2013
205. Zhou, Z.; Ma, T.L.; Feng, L. Effects of polysaccharides from Portulaca oleracea L. on intestinal flora and blood endotoxin in mice with ulcerative colitis. Chin. J. Microecol. 2014, 26, 646-648
206. Mahowald, M.A.; Rey, F.E.; Seedorf, H.; Turnbaugh, P.J.; Fulton, R.S.; Wollam, A.; Shah, N.; Wang, C.; Magrini, V.; Wilson, R.K. et al. Characterizing a model human gut microbiota composed of members of its two dominant bacterial phyla. Proc. Natl. Acad. Sci. USA 2009, 106, 5859-5864
207. 4+ T Cells. BioMed Res. Int. 2015, 2015, 1-13
208. LI Cheng-De, Z.; Wen-Bin, S.; Yan, F.; YU, L.; Mao, J.S. Effect of Astragalus Polysaccharides on Th17/Treg Cytokines and Pulmonary Inflammation in Asthmatic Rats. Chin. Pharmacol. Bull. 2013, 29, 1275-1278
209. Govers, M.J.A.P.; Gannon, N.J.; Dunshea, F.; Gibson, P.R.; Muir, J.G. Wheat bran affects the site of fermentation of resistant starch and luminal indexes related to colon cancer risk: A study in pigs. Gut 1999, 45, 840-847
210. Rombeau, J.L.; Kripke, S.A. Metabolic and Intestinal Effects of Short-Chain Fatty Acids. J. Parenter. Enter. Nutr. 1990, 14, 181S-185S
211. Scheppach, W. Effects of short chain fatty acids on gut morphology and function. Gut 1994, 35, S35-S38
212. Säemann, M.D.; Österreicher, C.H.; Diakos, C.; Stöckl, J.; Zlabinger, G.J.; Böhmig, G.A.; Burtscher, H.; Parolini, O.; Hörl, W.H. Anti-inflammatory effects of sodium butyrate on human monocytes: Potent inhibition of IL-12 and up-regulation of IL-10 production. FASEB J. 2000, 14, 2380-2382
213. Segain, J.P.; De La Blétiere, D.R.; Bourreille, A.; Leray, V.; Gervois, N.; Rosales, C.; Ferrier, L.; Bonnet, C.; Blottiere, H.M.; Galmiche, J.P. Butyrate inhibits inflammatory responses through NFκB inhibition: Implications for Crohn’s disease. Gut 2000, 47, 397-403
214. Kanauchi, O.; Matsumoto, Y.; Matsumura, M.; Fukuoka, M.; Bamba, T. The Beneficial Effects of Microflora, Especially Obligate Anaerobes, and Their Products on the Colonic Environment in Inflammatory Bowel Disease. Curr. Pharm. Des. 2005, 11, 1047-1053
215. Lührs, H.; Gerke, T.; Muller, J.G.; Melcher, R.; Schauber, J.; Boxberger, F.; Scheppach, W.; Menzel, T. Butyrate Inhibits NF-κB Activation in Lamina Propria Macrophages of Patients with Ulcerative Colitis. Scand. J. Gastroenterol. 2002, 37, 458-466
216. Scheppach, W. German-Austrian Scfa Study Group Treatment of distal ulcerative colitis with short-chain fatty acid enemas a placebo-controlled trial. Dig. Dis. Sci. 1996, 41, 2254-2259
217. Kanauchi, O.; Agata, K. Protein, and Dietary Fiber-rich New Foodstuff from Brewer’s Spent Grain Increased Excretion of Feces and Jejunum Mucosal Protein Content in Rats. Biosci. Biotechnol. Biochem. 1997, 61, 29-33
218. Kanauchi, O.; Mitsuyama, K.; Homma, T.; Takahama, K.; Fujiyama, Y.; Andoh, A.; Araki, Y.; Suga, T.; Hibi, T.; Naganuma, M. et al. Treatment of ulcerative colitis patients by long-term administration of germinated barley foodstuff: Multi-center open trial. Int. J. Mol. Med. 2003, 12, 701-704
219. Kanauchi, O.; Iwanaga, T.; Andoh, A.; Araki, Y.; Nakamura, T.; Mitsuyama, K.; Suzuki, A.; Hibi, T.; Bamba, T. Dietary fiber fraction of germinated barley foodstuff attenuated mucosal damage and diarrhea, and accelerated the repair of the colonic mucosa in an experimental colitis. J. Gastroenterol. Hepatol. 2001, 16, 160-168
220. Araki, Y.; Andoh, A.; Koyama, S.; Fujiyama, Y.; Kanauchi, O.; Bamba, T. Effects of Germinated Barley Foodstuff on Microflora and Short Chain Fatty Acid Production in Dextran Sulfate Sodium-induced Colitis in Rats. Biosci. Biotechnol. Biochem. 2000, 64, 1794-1800
221. Shiba, T.; Aiba, Y.; Ishikawa, H.; Ushiyama, A.; Takagi, A.; Mine, T.; Koga, Y. The Suppressive Effect of Bifidobacteria on Bacteroides vulgatus a Putative Pathogenic Microbe in Inflammatory Bowel Disease. Microbiol. Immunol. 2003, 47, 371-378
222. Gupta, P.; Andrew, H.; Kirschner, B.S.; Guandalini, S. Is Lactobacillus GG Helpful in Children With Crohn’s Disease? Results of a Preliminary, Open-Label Study. J. Pediatr. Gastroenterol. Nutr. 2000, 31, 453-457
223. Kanauchi, O.; Nakamura, T.; Agata, K.; Mitsuyama, K.; Iwanaga, T. Effects of germinated barley foodstuff on dextran sulfate sodium-induced colitis in rats. J. Gastroenterol. 1998, 33, 179-188
224. Setoyama, H.; Imaoka, A.; Ishikawa, H.; Umesaki, Y. Prevention of gut inflammation by Bifidobacterium in dextran sulfate-treated gnotobiotic mice associated with Bacteroides strains isolated from ulcerative colitis patients. Microbes Infect. 2003, 5, 115-122
225. Cherbut, C.; Michel, C.; Lecannu, G. The Prebiotic Characteristics of Fructooligosaccharides Are Necessary for Reduction of TNBS-Induced Colitis in Rats. J. Nutr. 2003, 133, 21-27
226. Matsumoto, S.; Watanabe, N.; Imaoka, A.; Okabe, Y. Preventive Effects of Bifidobacteriumand Lactobacillus-Fermented Milk on the Development of Inflammatory Bowel Disease in Senescence-Accelerated Mouse P1/Yit Strain Mice. Digestion 2001, 64, 92-99
227. Videla, S.; Vilaseca, J.; Antolín, M.; García-Lafuente, A.; Guarner, F.; Crespo, E.; Casalots, J.; Salas, A.; Malagelada, J.R. Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat. Am. J. Gastroenterol. 2001, 96, 1486-1493
228. Schneeman, B.O. Fiber, Inulin and Oligofructose: Similarities and Differences. J. Nutr. 1999, 129, 1424S-1427S
229. Kleessen, B.; Hartmann, L.; Blaut, M. Oligofructose and long-chain inulin: Influence on the gut microbial ecology of rats associated with a human faecal flora. Br. J. Nutr.2001, 86, 291-300
230. Hoentjen, F.; Welling, G.W.; Harmsen, H.J.M.; Zhang, X.; Snart, J.; Tannock, G.W.; Lien, K.; A Churchill, T.; Lupicki, M.; A Dieleman, L. Reduction of Colitis by Prebiotics in HLA-B27 Transgenic Rats Is Associated with Microflora Changes and Immunomodulation. Inflamm. Bowel Dis. 2005, 11, 977-985
231. Dignass, A.; Lindsay, J.O.; Sturm, A.; Windsor, A.; Colombel, J.-F.; Allez, M.; D’Haens, G.; D’Hoore, A.; Mantzaris, G.; Novacek, G. et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. J. Crohn’s Coliti 2012, 6, 991-1030
232. Nerstedt, A.; Nilsson, E.C.; Ohlson, K.; Håkansson, J.; Svensson, L.T.; Löwenadler, B.; Svensson, U.K.; Mahlapuu, M. Administration of Lactobacillus evokes coordinated changes in the intestinal expression profile of genes regulating energy homeostasis and immune phenotype in mice. Br. J. Nutr. 2007, 97, 1117-1127
233. Barbosa, T.M.; Serra, C.R.; La Ragione, R.M.; Woodward, M.J.; Henriques, A.O. Screening for Bacillus Isolates in the Broiler Gastrointestinal Tract. Appl. Environ. Microbiol. 2005, 71, 968-978
234. Resta-Lenert, S.; E Barrett, K. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003, 52, 988-997
235. Peluso, I.; Fina, D.; Caruso, R.; Stolfi, C.; Caprioli, F.; Fantini, M.C.; Caspani, G.; Grossi, E.; Di Iorio, L.; Paone, F.M. et al. Lactobacillus paracasei subsp. paracasei B21060 Suppresses Human T-Cell Proliferation. Infect. Immun. 2007, 75, 1730-1737
236. Cary, V.A.; Boullata, J. What is the evidence for the use of probiotics in the treatment of inflammatory bowel disease? J. Clin. Nurs. 2010, 19, 904-916
237. Zocco, M.A.; Verme, L.Z.D.; Cremonini, F.; Piscaglia, A.C.; Nista, E.C.; Candelli, M.; Novi, M.; Rigante, D.; Cazzato, I.A.; Ojetti, V. et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 2006, 23, 1567-1574
238. Oliva, S.; Di Nardo, G.; Ferrari, F.; Mallardo, S.; Rossi, P.; Patrizi, G.; Cucchiara, S.; Stronati, L. Randomised clinical trial: The effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment. Pharmacol. Ther. 2012, 35, 327-334
239. Henker, J.; Laass, M.W.; Schreiner, A.; Schulze, J.; Müller, S. Probiotic Escherichia coli Nissle 1917 (EcN) for Successful Remission Maintenance of Ulcerative Colitis in Children and Adolescents: An Open-Label Pilot Study. Z. Gastroenterol. 2008, 46, 874-875
240. Kruis, W.; Schütz, E.; Fric, P.; Fixa, B.; Judmaier, G.; Stolte, M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 1997, 11, 853-858
241. Kato, K.; Mizuno, S.; Umesaki, Y.; Ishii, Y.; Sugitani, M.; Imaoka, A.; Otsuka, M.; Hasunuma, O.; Kurihara, R.; Iwasaki, A. et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment. Pharmacol. Ther. 2004, 20, 1133-1141
242. Guslandi, M. Saccharomyces Boulardii Plus Rifaximin in Mesalamine-intolerant Ulcerative Colitis. J. Clin. Gastroenterol. 2010, 44, 1
243. Venturi; Gionchetti, P.; Rizzello, F.; Johansson, R.; Zucconi, E.; Brigidi, P.; Matteuzzi, D.; Campieri, M. Impact on the composition of the faecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment. Pharmacol. Ther. 1999, 13, 1103-1108
244. Sood, A.; Midha, V.; Makharia, G.K.; Ahuja, V.; Singal, D.; Goswami, P.; Tandon, R.K. The Probiotic Preparation, VSL#3 Induces Remission in Patients With Mild-to-Moderately Active Ulcerative Colitis. Clin. Gastroenterol. Hepatol. 2009, 7, 1202-1209
245. Tursi, A.; Brandimarte, G.; Papa, A.; Giglio, A.; Elisei, W.; Giorgetti, G.M.; Forti, G.; Morini, S.; Hassan, C.; Pistoia, M.A. et al. Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study. Am. J. Gastroenterol. 2010, 105, 2218-2227
246. Mardini, H.E.; Grigorian, A.Y. Probiotic mix VSL# 3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: A meta-analysis. Inflamm. Bowel Dis.2014, 20, 1562-1567
247. Jijon, H.; Backer, J.; Diaz, H.; Yeung, H.; Thiel, D.; McKaigney, C.; De Simone, C.; Madsen, K. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 2004, 126, 1358-1373
248. Lee, J.; Rachmilewitz, D.; Raz, E. Homeostatic Effects of TLR9 Signaling in Experimental Colitis. Ann. N. Y. Acad. Sci. 2006, 1072, 351-355
249. McCarthy, J.; Sheil, B.; O’Mahony, L.; Bennett, M.; Ryan, P.; FitzGibbon, J.; Kiely, B.; Collins, J.; Shanahan, F. Is the Mucosal Route of Administration Essential for Probiotic Function? Subcutaneous Administration is Associated with Attenuation of Murine Colitis and Arthritis. Endoscopy 2004, 36, 694-700
250. Roller, M.; Rechkemmer, G.; Watzl, B. Prebiotic Inulin Enriched with Oligofructose in Combination with the Probiotics Lactobacillus rhamnosus and Bifidobacterium lactisModulates Intestinal Immune Functions in Rats. J. Nutr. 2004, 134, 153-156
251. Ishikawa, H.; Akedo, I.; Umesaki, Y.; Tanaka, R.; Imaoka, A.; Otani, T. Randomized Controlled Trial of the Effect of Bifidobacteria-Fermented Milk on Ulcerative Colitis. J. Am. Coll. Nutr. 2003, 22, 56-63
252. Laake, K.O.; Line, P.-D.; Aabakken, L.; Løtveit, T.; Bakka, A.; Eide, J.; Røsetti, A.; Grzyb, K.; Bjørneklett, A.; Vatn, M.H. et al. Assessment of Mucosal Inflammation and Circulation in Response to Probiotics in Patients Operated with Ileal Pouch Anal Anastomosis for Ulcerative Colitis. Scand. J. Gastroenterol. 2003, 38, 409-414
253. Furrie, E.; Macfarlane, S.; Kennedy, A.; Cummings, J.H.; Walsh, S.V.; A O’Neil, D.; Macfarlane, G.T. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: A randomised controlled pilot trial. Gut 2005, 54, 242-249
254. Ishikawa, H.; Matsumoto, S.; Ohashi, Y.; Imaoka, A.; Setoyama, H.; Umesaki, Y.; Tanaka, R.; Otani, T. Beneficial Effects of Probiotic Bifidobacterium and Galacto-Oligosaccharide in Patients with Ulcerative Colitis: A Randomized Controlled Study. Digestion 2011, 84, 128-133
255. Kanamori, Y.; Hashizume, K.; Sugiyama, M.; Morotomi, M.; Yuki, N. CASE REPORT: Combination Therapy with Bifidobacterium breve, Lactobacillus casei, and Galactooligosaccharides Dramatically Improved the Intestinal Function in a Girl with Short Bowel Syndrome: A Novel Synbiotics Therapy for Intestinal Failure. Dig. Dis. Sci. 2001, 46, 2010-2016
256. Berg, D.; Clemente, J.C.; Colombel, J.-F. Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome? Expert Rev. Gastroenterol. Hepatol. 2015, 9, 781-795
257. Van Nood, E.; Vrieze, A.; Nieuwdorp, M.; Fuentes, S.; Zoetendal, E.G.; De Vos, W.M.; Visser, C.E.; Kuijper, E.J.; Bartelsman, J.F.; Tijssen, J.G. et al. Duodenal Infusion of Donor Feces for RecurrentClostridium difficile. N. Engl. J. Med. 2013, 368, 407-415
258. Bennet, J.; Brinkman, M. Treatment of Ulcerative Colitis by Implantation of Normal Colonic Flora. Lancet 1989, 333, 164
259. Cui, B.; Feng, Q.; Wang, H.; Wang, M.; Peng, Z.; Li, P.; Huang, G.; Liu, Z.; Wu, P.; Fan, Z. et al. Fecal microbiota transplantation through mid-gut for refractory C rohn’s disease: Safety, feasibility, and efficacy trial results. J. Gastroenterol. Hepatol. 2015, 30, 51-58
260. Anderson, J.L.; Edney, R.J.; Whelan, K. Systematic review: Faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment. Pharmacol. Ther. 2012, 36, 503-516
261. Kunde, S.; Pham, A.; Bonczyk, S.; Crumb, T.; Duba, M.; Conrad, H., Jr.; Cloney, D.; Kugathasan, S. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 2013, 56, 597-601
262. Rossen, N.G.; Fuentes, S.; Van Der Spek, M.J.; Tijssen, J.G.; Hartman, J.H.; Duflou, A.; Lowenberg, M.; Brink, G.R.V.D.; Mathus-Vliegen, E.M.; De Vos, W.M. et al. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology 2015, 149, 110-118
263. Angelberger, S.; Reinisch, W.; Makristathis, A.; Lichtenberger, C.; Dejaco, C.; Papay, P.; Novacek, G.; Trauner, M.; Loy, A.; Berry, D. Temporal Bacterial Community Dynamics Vary Among Ulcerative Colitis Patients After Fecal Microbiota Transplantation. Am. J. Gastroenterol. 2013, 108, 1620-1630
264. Kump, P.K.; Gröchenig, H.-P.; Lackner, S.; Trajanoski, S.; Reicht, G.; Hoffmann, K.M.; Deutschmann, A.; Wenzl, H.H.; Petritsch, W.; Gorkiewicz, G. et al. Alteration of Intestinal Dysbiosis by Fecal Microbiota Transplantation Does not Induce Remission in Patients with Chronic Active Ulcerative Colitis. Inflamm. Bowel Dis. 2013, 19, 2155-2165
265. Rossen, N.G.; Macdonald, J.K.; De Vries, E.M.; D’Haens, G.R.; De Vos, W.M.; Zoetendal, E.G.; Ponsioen, C.Y. Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review. World J. Gastroenterol. 2015, 21, 5359-5371.